Evidence map›Paper›PMID 41008573›Full record

ReviewBiomolecules2025

From Obscurity to Prominence: IPMK's Expanding Role in Cellular Signaling, Physiology, and Disease.

Subrata H Mishra, Sujan Chatterjee, Loretta Viera-Preval, Prasun Guha

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Subrata H MishraInstitute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, University of Maryland, Rockville, MD 20850, USA.ORCID 0000-0002-1515-3427
Sujan ChatterjeeNevada Institute of Personalized Medicine, University of Nevada, Las Vegas, NV 89154, USA.ORCID 0009-0000-2281-9066
Loretta Viera-PrevalNevada Institute of Personalized Medicine, University of Nevada, Las Vegas, NV 89154, USA.
Prasun GuhaNevada Institute of Personalized Medicine, University of Nevada, Las Vegas, NV 89154, USA.ORCID 0000-0003-1224-7361

Funding

IPMK is a novel PI3k essential for mTORC2 activation and cell migrationR16GM154726 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI Prasun Guha · 2024 to 2026
$563k
NIGMS NIH HHS R16 GM154726
6 · The paper itself

Abstract

Once a protein of relative obscurity, inositol polyphosphate multikinase (IPMK) emerged as a versatile and indispensable enzyme in cellular biology. With dual inositol and lipid kinase activities, IPMK generates pivotal signaling molecules such as InsP4 (inositol tetraphosphate), InsP5 (inositol pentaphosphate), and PIP3 (phosphoinositide 3,4,5-trisphosphate), positioning it as a critical regulator of cellular mechanisms. Initially identified in yeast and later recognized as essential for mammalian embryonic development, IPMK has transitioned from a niche interest to a focal point in studies of nutrient sensing, growth factor signaling, mRNA transport, and transcription regulation. Over two decades, multidisciplinary research has unveiled its far-reaching biological roles and implications in diverse diseases, including neurodegeneration, cancer, and inflammation. This review charts IPMK's journey from obscurity to prominence, examining its structure-function relationships, cellular roles, and emerging physiological impacts, while highlighting its potential as a therapeutic target in human health and disease.

Indexed as

Phosphotransferases (Alcohol Group Acceptor)Signal TransductionAnimalsHumansNeoplasmsinositol polyphosphate multikinasePhosphotransferases (Alcohol Group Acceptor)cell migrationDNA repairHOIPinositolInsPIPMKmTORphysiologyPIP3

Identifiers

PMID41008573
PMCPMC12467090

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.